Human immunodeficiency virus type 1 (HIV-1) Vpu enhances the release of viral particles from infected cells by interfering with the function of BST-2/tetherin, a cellular protein inhibiting virus release. The Vpu protein encoded by NL4-3, a widely used HIV-1 laboratory strain, antagonizes human BST-2 but not monkey or murine BST-2, leading to the conclusion that BST-2 antagonism by Vpu is species specific. In contrast, we recently identified several primary Vpu isolates, such as Vpu of HIV-1_DH12, capable of antagonizing both human and rhesus BST-2. Here we report that while Vpu interacts with human BST-2 primarily through their respective transmembrane domains, antagonism of rhesus BST-2 by Vpu involved an interaction of their cytoplasmic domains. Importantly, a Vpu mutant carrying two mutations in its transmembrane domain (A14L and W22A), rendering it incompetent for interaction with human BST-2, was able to interact with human BST-2 carrying the rhesus BST-2 cytoplasmic domain and partially neutralized the ability of this BST-2 variant to inhibit viral release. Bimolecular fluorescence complementation analysis to detect Vpu–BST-2 interactions suggested that the physical interaction of Vpu with rhesus or chimpanzee BST-2 involves a 5-residue motif in the cytoplasmic domain of BST-2 previously identified as important for the antagonism of monkey and great ape BST-2 by simian immunodeficiency virus (SIV) Nef. Thus, our study identifies a novel mechanism of antagonism of monkey and great ape BST-2 by Vpu that targets the same motif in BST-2 used by SIV Nef and might explain the expanded host range observed for Vpu isolates in our previous study.

BST-2 (also referred to as tetherin, CD317, or HM1.24) is an interferon-inducible transmembrane (TM) protein that was originally identified in terminally differentiated human B cells of patients with multiple myeloma (1, 2). The protein consists of approximately 180 amino acids that include a short N-terminal cytoplasmic domain, a TM domain, and a rod-like α-helical ectodomain with the propensity, at least in vitro, to form a rod-like coiled-coil structure (3–8). The BST-2 C terminus is made up of a stretch of hydrophobic residues that, in rat BST-2, has been determined to function as a glycosylphosphatidylinositol (GPI) anchor signal (4). Recent experimental evidence suggests that in human BST-2 (huBST-2), this C-terminal hydrophobic domain may constitute a second TM domain rather than a GPI anchor signal (9). As far as the BST-2 ectodomain is concerned, it contains three cysteine residues important for the formation of covalent cysteine-linked dimers, as well as two N-linked carbohydrate side chains whose functional importance is currently unclear (1, 2, 4, 10, 11). BST-2 associates with lipid rafts at the cell surface and on internal membranes (4, 12–15).

While the physiological function of BST-2 in uninfected cells remains unclear, BST-2 has recently been shown to inhibit the release of human immunodeficiency virus type 1 (HIV-1) (16, 17). In fact, inhibition of virus release by BST-2 is not HIV-1 specific but affects other lentiviruses, such as HIV-2 and simian immunodeficiency virus (SIV), as well as a wide variety of enveloped viruses, including Ebola virus, Lassa virus, Marburg virus, Kaposi sarcoma-associated herpesvirus (KSHV), porcine endogenous retrovirus (PERV), and endogenous betaretrovirus of sheep (18–23). Three different lentiviral proteins, HIV-1 Vpu, HIV-2 Env, and SIV Nef, have been found to antagonize the activity of their natural host, BST-2, thus allowing for efficient particle release from BST-2-expressing cells. They are either TM proteins, like BST-2 (Vpu, Env), or are membrane associated by means of a myristic acid modification (Nef). All of them are thought to interfere with BST-2 function through direct physical interaction (24–33). Aside from these lentiviral proteins, the KSHV-encoded ubiquitin ligase K5 has been found to antagonize BST-2 by inducing ubiquitin-mediated endocytosis and lysosomal degradation of BST-2 (34, 35).

A current model suggests that BST-2 tethers mature virions to the cell surface by means of its N-terminal TM region and C-terminal membrane anchor. Indeed, immune electron microscopy identified BST-2 on virions tethered to the cell surface and on particles tethered to each other (11, 36–39). Interestingly, artificial tetherin consisting of the N-terminal TM region of transferrin receptor, a coiled-coil ectodomain of the cytoplasmic dimeric protein dystrophia myotonica protein kinase, and a GPI anchor signal derived from urokinase plasminogen activator receptor was capable of inhibiting the release of HIV-1 virions tethered to the cell surface (11). This suggests that the secondary structure rather than the primary amino acid sequence of BST-2 is important for its tethering function. Indeed, our own studies investigating the importance of structural elements in the BST-2 ectodomain revealed surprising flexibility in the size of the BST-2 ectodomain. Both increases and decreases in the size of the ectodomain, as well as replacement of the C-terminal hydrophobic domain by heterologous TM domains, were functionally tolerated (9, 40).

The widely used HIV-1 laboratory strain NL4-3 encodes a Vpu
protein that is able to target human BST-2 but not murine or monkey BST-2, leading to the notion that Vpu antagonism of BST-2 is species specific (41–46). More-recent evidence, indicates that other Vpu proteins, such as the Vpu encoded by the clinical isolate HIV-1DH12, have a less restricted phenotype and are able to antagonize not only human BST-2 but rhesus BST-2 (rBST-2) as well (47). Transfer of the TM domain from HIV-1 DH12 Vpu was sufficient to render HIV-1NL4-3 Vpu capable of antagonizing rhesus BST-2 (47). The importance of the TM domain in Vpu for antagonism of BST-2 was affirmed by the finding that a single amino acid change in the TM domain of rhesus BST-2 (I48T) rendered the protein sensitive to HIV-1 NL4-3 Vpu in a gain-of-function analysis (48). Similarly, the change of a single amino acid in the TM domain of human BST-2 to the corresponding residue found in the BST-2 protein of the Tantalus monkey (T45I) rendered the protein insensitive to HIV-1 Vpu in a loss-of-function study (42). Thus, all available evidence points to a functional interaction of the TM domains of Vpu and rhesus BST-2 as necessary and sufficient for functional neutralization of rhesus BST-2.

In an extension of these studies, we designed experiments to confirm that the expanded host range associated with the transfer of the DH12 Vpu TM domain to NL4-3 Vpu was due to a gain of interaction between Vpu and rhesus BST-2. Surprisingly, binding studies revealed that the nonfunctional NL4-3 Vpu interacted with rhesus BST-2 as efficiently as the functional Vpu variant, VpuDH12, suggesting that the interaction of Vpu and BST-2 was necessary but not sufficient for the functional neutralization of BST-2 and may involve sequences in the cytoplasmic domain of Vpu. Indeed, we found that while HIV-1 Vpu, as expected, interacted with human BST-2 primarily through their respective TM domains, the physical association with rhesus BST-2 was at least in part, mediated by their cytoplasmic domains. Importantly, a Vpu mutant carrying two mutations in its TM domain (A14L and W25A) rendering it incompetent for interaction with human BST-2 was capable not only of interacting with human BST-2 carrying the rhesus BST-2 cytoplasmic domain (huBST-2CYTTH secretion but also of partially antagonizing huBST-2 in a functional assay. Analyses of additional BST-2 variants revealed that the physical interaction of Vpu and rhesus BST-2 involves a 5-residue motif in the cytoplasmic domain of rhesus BST-2. The same motif is conserved in chimpanzee BST-2 (chimpBST-2) and is critical for the interaction with Vpu. Interestingly, this motif was previously identified as important for antagonism of rhesus and chimpanzee BST-2 by SIV Nef (43, 44, 49–51). Thus, our data identify a novel mechanism of antagonism of rhesus BST-2 by Vpu that targets the same motif in the cytoplasmic domain of BST-2 used by SIV Nef.

**MATERIALS AND METHODS**

**Plasmids.** The construction of plasmid pNL4-3, encoding the laboratory-adapted full-length molecular HIV-1 isolate NL4-3 (52), its Vpu-deficient variant pNL4-3/Udel (53), and pNL4-3 Vpu tmDH12, encoding a chimera pNL4-3 Vpu DH12, have been described previously. Vectors for the expression of endogenous human and rhesus BST-2 (huBST-2 and rBST-2, respectively) have been described previously (48, 54). In addition, rBST-2148T, carrying a mutation in its TM domain, rBST-2148Tcha, encoding the human cytoplasmic domain, and rBST-2148T, carrying the human TM domain, have been described previously (48). Plasmids pKGC-huBST-2, pKGN-Vpu, pKGN-VpuTMd, and pKGNstop, for analyzing the interaction of Vpu and BST-2 in live cells, have been described previously (25). All mutants were created by overlapping extension PCR, and the resulting DNA fragments were subcloned into the pNL4-3, pcDNA3.1(−) (Invitrogen Corp., Carlsbad, CA), pkmKGC-MC, or pkmKGN-MN (MBL International, Woburn, MA) vector backbone. The nucleotide sequence of each construct was verified by sequence analysis. The open reading frame of codon-optimized SIVcpzMB897 Vpu was generated by single-step assembly of 6 oligodeoxyribonucleotides (55) according to the algorithm reported for codon-optimized NL4-3 Vpu (56) and was subcloned into pkmKGN-MN. The chimpanzee BST-2 open reading frame (ORF) was amplified from pCGGC-chimpanzee BST-2 (provided by Frank Kirchhoff (43)).

**Cell culture and transfection.** HEK293T (293T) cells grown in 6-well plates were transfected with appropriate pairs of constructs (1 μg each) tagged with the N- or C-terminal fragment of Kusabira green (KGN or KGC, respectively) and 2 μg of mCherry-expressing plasmid as a transfection marker (provided by Juan Martin-Serrano). Forty-eight hours posttransfection, cells were washed with phosphate-buffered saline (PBS), scraped, and resuspended in 2 ml of PBS. One fraction (0.5 ml) of the cell suspension was analyzed on a FACS-Calibur flow cytometer (BD Biosciences Immunocytometry Systems, Mountain View, CA) as described previously (25, 57). The mean fluorescent intensities (MFI) of bimolecular fluorescence complementation (BiFC) signals in mCherry-positive cells are shown in the figures. The remaining cells (1.5 ml) were pelleted, resuspended in 100 μl of PBS, and mixed with an equal volume of 2× sample buffer (4% sodium dodecyl sulfate, 125 mM Tris-HCl [pH 6.8], 10% 2-mercaptoethanol [ME], 10% glycerol, 0.002% bromophenol blue). Samples were heated at 95°C for 10 min with occasional vortexing. Cell lysates were subjected to SDS-PAGE; proteins were transferred to polyvinylidine difluoride membranes and were reacted with an anti-KGN or anti-KGC monoclonal antibody (MAB) (MBL International, Woburn, MA). Membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (Amer sham Biosciences, Piscataway, NJ), and proteins were visualized by enhanced chemiluminescence (Amersham Biosciences).

**Virus release assay.** The release of newly produced virions was measured by determining the efficiency of release of metabolically labeled viral Gag proteins. Cells were grown in 25-cm² flasks and were transfected as described above with constant amounts of proviral vectors and increasing amounts of nontagged BST-2-encoding vectors. Total amounts of transfected DNA were kept constant in all samples of a given experiment (typically 5.2 μg) by adding empty-vector DNA as appropriate. Twenty-four hours later, cells were washed with PBS, scraped, and suspended in 3 ml of a labeling medium lacking methionine and cysteine (Millipore Corp., Bedford, MA). Cells were incubated for 10 min at 37°C to deplete the endogenous methionine pool. Cells were then suspended in 400 μl of the labeling medium together with 150 μCi of Expre35S35S P protein labeling mix (Perkin-Elmer, Shelton, CT). Cells were labeled for 90 min at 37°C. Cells and virus-containing supernatants were then separated by centrifugation and were processed separately for immunoprecipitation. To identify HIV-1-specific proteins, cells were lysed in 600 μl of NP-40–deoxycholate (DOC) lysis buffer (20 mM Tris [pH 7.5], 2 mM EDTA, 20 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate) and were incubated on ice for 5 min. Insoluble material was pelleted at 13,000 × g for 2 min, and supernatants were used for immunoprecipitation. Virus-containing supernatants were treated with 200 μl of 3× NP-40–DOC lysis buffer to disrupt viral membranes. Cell and virus lysates were adjusted to a 1.1-ml total volume with PBS containing bovine serum albumin (BSA; final concentration, 0.1%) and were incubated on a rotating wheel for 1 h at 4°C with protein A-Sepharose coupled with serum from an HIV-positive pa...
tient. Beads were washed three times with wash buffer (50 mM Tris [pH 7.4], 300 mM NaCl, 0.1% Triton X-100). Bound proteins were eluted by heating in 1 × sample buffer (2% sodium dodecyl sulfate, 62.5 mM Tris-HCl [pH 6.8], 5% 2-mercaptoethanol, 5% glycerol, and 0.001% bromophenol blue) for 10 min at 95°C, separated by SDS-PAGE, and visualized by fluorography. Virus release was quantified by phosphorimaging analysis using a Fujifilm FLA7000 system. The fraction of p24 released in the absence of BST-2 relative to the total amount of intra- and extracellular Gag protein was defined as 100%.

**Pulse-chase analysis.** The pulse-chase assay is similar to the virus release assay except that viral release kinetics are determined by collecting samples at multiple time points over an observation period as described previously (58). Briefly, cells grown in 25-cm² flasks were transfected with 5 μg of pNL4-3/Udel, 0.01 μg of pKGC-chimpBST-2, and 0.5 μg of constructs expressing KGN-tagged Vpu or the KGN tag only. Twenty-four hours later, cells were labeled for 30 min at 37°C as described for the virus release assay. The isotope was then removed, and cells were chased in complete DMEM–FBS for the times indicated in Fig. 6C. At each time point, cells and supernatant were collected separately, lysed in NP-40–DOC lysis buffer, and immunoprecipitated as described for the virus release assay.

**TZM-bl assay.** The TZM-bl assay was carried out essentially as described previously (40). Virus stocks were prepared by transfection of 293T cells. Virus-containing supernatants were harvested 24 h after transfection. Cellular debris was removed by centrifugation (3 min, 1,500 × g). One hundred microliters of viral supernatant was used to infect 5 × 10⁴ TZM-bl cells in a 24-well plate in a total volume of 1.1 ml containing 1 μM ritonavir (NIH AIDS Research and Reference Reagent Program, catalog no. 4622). Infection was allowed to proceed for 48 h at 37°C. The medium was removed; cells were lysed in 300 μl of 1× reporter lysis buffer (Promega Corp., Madison, WI), and lysates were frozen at −80°C for a minimum of 30 min. To determine the luciferase activity in the lysates, 5 μl of each lysate was combined with 20 μl of a luciferase substrate (Steady-Glo; Promega Corp., Madison, WI), and light emission was measured using a Modulus II microplate reader (Turner BioSystems Inc., Sunnyvale, CA).

**Statistical analysis.** To determine statistical significance, Student’s t tests and two-way analyses of variance (ANOVA) were carried out using GraphPad Prism (version 6) for the BiFC interaction assay and the functional assays (the virus release, pulse-chase, and TZM-bl assays), respectively.

**RESULTS**

**The interaction of rhesus BST-2 with HIV-1 Vpu involves the cytoplasmic domain.** To gain a better understanding of the physical and functional interaction between Vpu and BST-2, we chose to carry out a live-cell protein-protein interaction assay based on bimolecular fluorescence complementation (BiFC) (59, 60). The BiFC approach is based on complementation between two fragments of a fluorescent protein such as Kusabira green (KG) (61). Individual fragments such as the N- and C-terminal fragments of KG (referred to as KGN and KGC, respectively) are not fluorescent by themselves; however, reconstitution of a complex by these fragments brought together by the association of two interaction partners fused to the fragments restores fluorescence and allows for quantitative analysis of protein complexes using flow cytometry (25, 57).

We started out by assessing the molecular interaction between HIV-1 Vpu and BST-2 by using the BiFC assay. For that purpose, we used N-terminally KGC-tagged BST-2 constructs expressing huBST-2 (25), rhBST-2, or rhBST-2ΔTMD as shown at the top of Fig. 1A. We also used C-terminally KGN-tagged NL4-3 Vpu constructs expressing wild-type (WT) Vpu (25), a mutant with a scrambled TM domain, VpuΔTD (25), or VpuΔTDH12 (Fig. 1A, bottom). After confirmation of protein expression by immunoblotting (Fig. 1B, top), the intensities of BiFC signals resulting from different levels of protein-protein interaction were measured by flow cytometry (Fig. 1B, bottom). Bars framed in red indicate combinations previously found to result in functional antagonism of BST-2 (47, 48). A strong BiFC signal was observed in cells transfected with huBST-2 and NL4-3 Vpu but not in cells expressing

![Figure 1](http://jvi.asm.org/Downloadedfromhttp://jvi.asm.org/)
cause we reported previously that mutation of I48T in the TM domain of rhesus BST-2 in the context of KGC- and KGN-tagged variants faithfully replicates previous results from studies using coimmunoprecipitation (co-IP) (26–28, 63), fluorescence resonance energy transfer (FRET) (64), nuclear magnetic resonance (NMR) spectroscopy (31), or BiFC (25). Finally, VpumDH12 carrying the TM domain of DH12 Vpu, which we previously found to antagonize both human and rhesus BST-2 (47), interacted with huBST-2, although the BiFC signal was not as strong as that observed with NL4-3 Vpu (Fig. 1B, compare bars 2 and 4). Nevertheless, the BiFC signal was significantly higher than that observed for VpuRD or the “tag-only” control (Fig. 1B, compare bar 4 with bar 3 or 1). The failure of VpuRD to produce significant BiFC signals when expressed in combination with huBST-2 indicates that the signal observed in conjunction with wild-type Vpu (Fig. 1B, bar 2) is specific and is not the result of random encounters of two membrane proteins in a 2-dimensional plane. Taken together, these results validate our BiFC assay as a suitable method for the assessment of molecular interactions between HIV-1 Vpu and host BST-2 in live cells.

We next assessed the interaction of Vpu with rhBST-2 in our BiFC assay (Fig. 1B, bars 5 to 8). NL4-3 Vpu does not antagonize rhBST-2 in a functional assay but was nevertheless found to interact with rhBST-2, even though the BiFC signal was lower than that for huBST-2 (Fig. 1B, compare bars 2 and 6). Of note, NL4-3 Vpu interacted with rhBST-2 almost as efficiently as VpumDH12, which is capable of functionally antagonizing rhBST-2 (Fig. 1B, compare bars 6 and 8). This suggests that VpumDH12 antagonizes rhBST-2 without increasing the physical interaction between the proteins. Surprisingly, VpuRD interacted with rhBST-2 as efficiently as NL4-3 Vpu (Fig. 1B, compare bars 6 and 7), even though it was unable to interact with huBST-2. To confirm this result, we also assessed the interaction between NL4-3 Vpu and rhBST-2I48T because we reported previously that mutation of I48T in the TM domain of rhesus BST-2 renders the protein sensitive to NL4-3 Vpu (48). Interestingly, NL4-3 Vpu produced similar BiFC signals when coexpressed with wild-type rhBST-2 or with rhBST-2I48T (Fig. 1B, compare bars 6 and 10), suggesting that the I48T mutation rendered rhesus BST-2 sensitive to NL4-3 Vpu without a noticeable increase in the physical interaction between the proteins. The same was true for VpuRD and VpumDH12, which produced very similar BiFC signals when coexpressed with wild-type rhBST-2 (Fig. 1B, bars 7 and 8) or rhBST-2I48T (Fig. 1B, bars 11 and 12). Given that the Vpu variants analyzed so far differed only in their TM domains, these results support the notion that Vpu interaction with rhBST-2 involves domains other than—or in addition to—the TM domain. Taking our findings together, we conclude that a physical interaction between Vpu and BST-2 may be necessary but is not sufficient for functional antagonism of BST-2 by Vpu, suggesting that physical interaction is only one step in a series of events that ultimately lead to antagonism of BST-2.

To test whether the interaction of Vpu with rhBST-2 involves additional sequences in the cytoplasmic domain, we generated KGC-tagged rhBST-2 variants carrying the human cytoplasmic domain (CYThu) or the human TM domain (TMhu). The constructs are shown schematically in Fig. 2A. After confirming the expression of the proteins by immunoblotting (Fig. 2B, top), we assessed the relative levels of protein-protein interaction by BiFC (Fig. 2B, bottom). As expected, the interaction of NL4-3 Vpu with rhBST-2TMhu was significantly stronger than that with wild-type rhBST-2 (Fig. 2B, compare bars 4 and 6), because the TM domain of human BST-2 contributes prominently to the interaction with NL4-3 Vpu. Nevertheless, the BiFC signal for rhBST-2 and NL4-3 Vpu was significantly above background (Fig. 2B, compare bars 1 and 4). Of note, the BiFC signal for NL4-3 Vpu and rhBST-2CYThu was lower than the signal for NL4-3 Vpu and rhBST-2 (Fig. 2B, compare bars 4 and 5), suggesting involvement of the rhBST-2 cytoplasmic domain in the interaction with Vpu. Consistent with these results, we found that the cytoplasmic domain of rhBST-2 also contributes to the interaction with VpuRD (Fig. 2B, compare bars 7 and 8).

The cytoplasmic domain of rhesus BST-2 is critical for functional antagonism by Vpu. We reported previously that VpumDH12, but not NL4-3 Vpu, was able to antagonize rhBST-2 (47). Given that the mutation of the Vpu TM domain in VpuRD inhibited binding to huBST-2 (Fig. 1B) and resulted in a loss of antagonizing activity toward huBST-2, we next investigated the relative importance of the cytoplasmic domain in rhBST-2 for functional
antagonism by Vpu. The BST-2 constructs used in this experiment are shown schematically in Fig. 3A. We first tested the ability of VputmDH12 to interact with rhBST-2 or rhBST-2CYThu (Fig. 3B). Protein expression was verified by immunoblotting (Fig. 3B, inset). BiFC analysis indeed demonstrated that coexpression of VputmDH12 with wild-type rhBST-2 produced a stronger BiFC signal than coexpression with rhBST-2CYThu, carrying the human cytoplasmic domain (Fig. 3B, compare bars 3 and 4). The change in the BiFC signal caused by the replacement of the rhBST-2 cytoplasmic domain with the huBST-2 cytoplasmic domain provides further evidence that the cytoplasmic domain of rhBST-2 contributes to the interaction with VputmDH12 (Fig. 3B).

The ability of Vpu to antagonize rhBST-2 or rhBST-2CYThu was assessed as described for panel C.
The BiFC signal measured for the interaction of wild-type Vpu and huBST-2CYTrh or Vpu or Vpu14/22 was quantified as described for Fig. 1B. The huBST-2BiFC signal resulting from the coexpression of NL4-3 and huBST-2 (bar 2) was defined as 100%, ***, P < 0.01. The expression of KGC-tagged huBST-2 and KGN-tagged proteins was assessed by immunoblotting as described for Fig. 1B. The KGN fragment encoded by the “tag-only” vector has a faster mobility and is not visible here. Faint bands in lane 1 are nonspecific background. (B) The functional antagonism of human BST-2 by Vpu variants was assessed by metabolic labeling as described for Fig. 3C. Filled circles, NL4-3 Vpu; open circles, NL4-3/Udel. Data are means plus standard errors of the means from three independent experiments. Statistical significance was determined by two-way ANOVA. ***,***, P < 0.01. Bars outlined in red represent combinations of Vpu with Vpu14/22 and huBST-2CYThu. Virus release in the absence of BST-2 (0 ug) was defined as 100%. Data are means plus standard errors of the means from three independent experiments. Statistical significance was determined by two-way ANOVA. ***, P < 0.01.

The ability of Vpu14/22 to antagonize huBST-2CYTrh was also assessed by measuring its effect on virus release using full-length NL4-3 carrying the mutation in its TM domain that renders it sensitive to NL4-3 Vpu (48). We also analyzed a derivative of rhBST-2I48T, rhBST-2CYThuI48T, additionally encoding the human cytoplasmic domain. We generated KGC-tagged as well as untagged forms of rhBST-2I48T and rhBST-2CYThuI48T (Fig. 3A). Protein expression was verified by immunoblotting (Fig. 3D, inset). BiFC analysis indicated that NL4-3 Vpu indeed interacted with rhBST-2I48T (Fig. 3D, bar 3). Again, the BiFC signal resulting from the coexpression of NL4-3 Vpu and rhBST-2CYThuI48T was weaker than that with rhBST-2I48T (Fig. 3D, compare bars 3 and 4), suggesting a significant contribution of the BST-2 cytoplasmic domain to the physical interaction of rhBST-2 and NL4-3 Vpu. Analysis of these constructs in our virus release assay confirmed that NL4-3 Vpu antagonizes rhBST-2I48T (Fig. 3E, left) (***, P < 0.0003), as reported previously (48). However, replacing the rhBST-2 cytoplasmic domain with the huBST-2 sequence caused a complete loss of Vpu sensitivity (Fig. 3E, right) (***, P = 0.679). From these loss-of-function studies, we conclude that the rhBST-2 cytoplasmic domain is important for the physical interaction with Vpu as well as for functional sensitivity to Vpu.

We next employed a gain-of-function approach to assess whether interaction between BST-2 and Vpu through their cytoplasmic domains is necessary for functional antagonism. For that purpose, we made use of an inactive NL4-3 Vpu mutant, VpuI14/22, carrying two amino acid changes (A14L, W22A) in its TM domain that renders it sensitive to NL4-3 Vpu (48). This mutant was previously shown to be unable to enhance virus release, to coimmunoprecipitate huBST-2, or to downregulate cell surface expression of huBST-2 (65). BiFC analyses indicate that huBST-2 indeed interacts only inefficiently with VpuI14/22 compared to NL4-3 Vpu (Fig. 4A, top, compare bars 2 and 3). Comparable expression of NL4-3 Vpu and VpuI14/22 as well as huBST-2 was verified by immunoblotting (Fig. 4A, bottom). The ability of VpuI14/22 to antagonize huBST-2 was assessed by measuring its effect on virus release using full-length NL4-3 carrying the mutant

\[ \text{(Fig. 3C). The contribution of the rhBST-2 cytoplasmic domain to Vpu responsiveness was tested by comparing the relative inhibition of virus release for wild-type (WT) NL4-3, NL4-3/Udel, and NL4-3 VpuI14/22. In these experiments, Vpu was expressed in the context of full-length viral genomes. In agreement with our previous observations (47), VpuI14/22, but not NL4-3 Vpu, was able to antagonize rhBST-2 (Fig. 3C, left, compare filled squares with open circles) (***, P = 0.0003). In contrast, neither VpuI14/22 nor NL4-3 Vpu was able to antagonize rhBST-2CYThu (Fig. 3C, right, compare filled squares and filled circles with open circles) (P, 0.36). These results indicate that even though rhBST-2 carrying the cytoplasmic domain of huBST-2 (rhBST-2CYThu) is able to inhibit HIV-1 release effectively, the presence of a human cytoplasmic domain abolished sensitivity to VpuI14/22 due to the reduced physical interaction.}

To further confirm the importance of the rhBST-2 cytoplasmic domain for the interaction with and antagonism by Vpu, we carried out similar experiments using rhBST-2I48T, carrying a mutation in its TM domain that renders it sensitive to NL4-3 Vpu (48). We also analyzed a derivative of rhBST-2I48T, rhBST-2CYThuI48T, additionally encoding the human cytoplasmic domain. We generated KGC-tagged as well as untagged forms of rhBST-2I48T and rhBST-2CYThuI48T (Fig. 3A). Protein expression was verified by immunoblotting (Fig. 3D, inset). BiFC analysis indicated that NL4-3 Vpu indeed interacted with rhBST-2I48T (Fig. 3D, bar 3). Again, the BiFC signal resulting from the coexpression of NL4-3 Vpu and rhBST-2CYThuI48T was weaker than that with rhBST-2I48T (Fig. 3D, compare bars 3 and 4), suggesting a significant contribution of the BST-2 cytoplasmic domain to the physical interaction of rhBST-2 and NL4-3 Vpu. Analysis of these constructs in our virus release assay confirmed that NL4-3 Vpu antagonizes rhBST-2I48T (Fig. 3E, left) (***, P < 0.0003), as reported previously (48). However, replacing the rhBST-2 cytoplasmic domain with the huBST-2 sequence caused a complete loss of Vpu sensitivity (Fig. 3E, right) (***, P = 0.679). From these loss-of-function studies, we conclude that the rhBST-2 cytoplasmic domain is important for the physical interaction with Vpu as well as for functional sensitivity to Vpu.

We next employed a gain-of-function approach to assess whether interaction between BST-2 and Vpu through their cytoplasmic domains is necessary for functional antagonism. For that purpose, we made use of an inactive NL4-3 Vpu mutant, VpuI14/22, carrying two amino acid changes (A14L, W22A) in its TM domain. This mutant was previously shown to be unable to enhance virus release, to coimmunoprecipitate huBST-2, or to downregulate cell surface expression of huBST-2 (65). BiFC analyses indicate that huBST-2 indeed interacts only inefficiently with VpuI14/22 compared to NL4-3 Vpu (Fig. 4A, top, compare bars 2 and 3). Comparable expression of NL4-3 Vpu and VpuI14/22 as well as huBST-2 was verified by immunoblotting (Fig. 4A, bottom). The ability of VpuI14/22 to antagonize huBST-2 was assessed by measuring its effect on virus release using full-length NL4-3 carrying the mutant interaction was assessed by metabolic labeling as described for Fig. 3C. Data are means plus standard errors of the means from three independent experiments. Statistical significance was determined by two-way ANOVA. ***, P < 0.01.
tions at amino acids 14 and 22 in Vpu (NL4-3 Vpu14/22). In agreement with the results reported by Vigan and Neil (65), we found that unlike wild-type Vpu, Vpu14/22 was unable to antagonize huBST-2 in our virus release assay (Fig. 4B, compare solid circles to solid squares). These results were confirmed in an independent assay employing infection of TZM-bl cells as a means to quantify virus release (Fig. 4C). The results are consistent with those of the virus release assay shown in Fig. 4B, demonstrating that wild-type NL4-3 Vpu (WT), but not Vpu14/22, enhances virus release in the presence of huBST-2 (Fig. 4C, compare solid circles and solid squares).

Next, we assessed the ability of Vpu14/22 to physically interact with and functionally counteract huBST-2 carrying the rhBST-2 cytoplasmic domain (huBST-2CYTrh). BiFC analysis revealed significant interaction of Vpu14/22 with huBST-2CYTrh compared to the vector control (Fig. 4D, compare bars 1 and 3), although the BiFC signal was slightly weaker than that observed for wild-type Vpu (Fig. 4D, compare bars 2 and 3). These results show that the cytoplasmic domain of rhBST-2 renders the protein capable of interacting with NL4-3 Vpu in the absence of TM domain interaction. To assess whether the interaction of Vpu14/22 with BST-2 via its cytoplasmic domain is sufficient for Vpu14/22 to functionally antagonize BST-2, we carried out our virus release assay (Fig. 4E), as well as the TZM-bl infection assay (Fig. 4F). Both assays demonstrated that the level of virus release from cells expressing huBST-2CYTrh in the presence of Vpu14/22 is significantly higher than that in the absence of Vpu (Fig. 4E and F, compare filled squares with open circles) (*P < 0.001, respectively). However, the antagonism of huBST-2CYTrh by Vpu14/22 was less efficient than that seen for wild-type Vpu (Fig. 4E and F, compare filled circles with filled squares) (**P = 0.007 and <0.0001, respectively). The results from this gain-of-function analysis therefore demonstrate that (i) a physical interaction between Vpu and BST-2 is necessary for functional antagonism and (ii) the interaction of Vpu with the cytoplasmic domain of rhBST-2 contributes at least in part to the expanded host range of Vpu.

A 5-amino-acid sequence in the rhesus BST-2 cytoplasmic domain accounts for the interaction with Vpu and for rhesus BST-2 antagonism by HIV-1 Vpu. One of the most prominent differences between the cytoplasmic domains of rhesus and human BST-2 is a 5-amino-acid segment [(G/D)DIWK] that is present in rhBST-2 but is missing in huBST-2 (Fig. 5A). This segment was previously identified as critical for the antagonism of monkey and great ape BST-2 by SIV Nef (43,44, 49). To investigate the importance of the (G/D)DIWK element for the interaction with NL4-3 Vpu, we deleted these five residues in rhBST-2 (Fig. 5A, rhBST-2AA). To control for the potential effect of the deletion, we also mutated these five residues to alanine (Fig. 5A, rhBST-2AA). Finally, since the cytoplasmic domains of human and rhesus BST-2 also differ in six positions at their extreme N termini, we replaced the six differing residues in rhBST-2 with the corresponding human sequences (Fig. 5A, rhBST-2AA). All mutants were transferred into the BiFC (KGC) vector, and expression of the KGC-tagged BST-2 variants and KGN-tagged Vpu was verified by immunoblotting (Fig. 5B, right). All proteins were expressed at comparable levels, except rhBST-2AA, whose expression was about 2-fold higher in this experiment (Fig. 5B, top right, lane 4). As expected from our results shown in Fig. 2B (bars 4 and 3), we detected a strong BiFC signal for the interaction of NL4-3 Vpu with wild-type rhBST-2 (Fig. 5B, bar 2) and a reduced signal for the interaction of Vpu with rhBST-2AA (Fig. 5B, bar 3). Deletion of the DDIIWK motif or its replacement with alanine resulted in similar reductions of the BiFC signals (Fig. 5B, bars 4 and 6, respectively). In contrast, replacement of six N-terminal residues by the human sequence did not significantly alter the BiFC signal (Fig. 5B, bar 5). The functional antagonism of rhesus BST-2 by Vpu was assessed in a virus release assay by metabolic labeling as described for Fig. 3C. Circles, NL4-3 (WT); squares, NL4-3 VpuAA (AA, P = 0.007). Data are means ± standard errors of the means from three independent experiments. Statistical significance was determined by two-way ANOVA. ***P < 0.01; n.s., P > 0.05.

Although NL4-3 Vpu can interact with rhBST-2 via its cytoplasmic domain, it is unable to functionally antagonize rhBST-2 unless it also encodes the TM domain of the DH12 isolate of Vpu (47). To assess whether the (G/D)DIWK motif similarly contributes to the functional antagonism of rhBST-2 by VpuAA, we
carried out our virus release assay using NL4-3 Vpu in the presence of either rhBST-2del5 (Fig. 5C, left) or rhBST-2Nhu (Fig. 5C, right). We found that Vpu was capable of functionally antagonizing rhBST-2Nhu (Fig. 5C, right) (***, P < 0.001). In contrast, neither Vpu variant was able to antagonize rhBST-2del5 (Fig. 5C, left) (P, 0.44). These results indicate that the 5-amino-acid DDIWK motif in the rhBST-2 cytoplasmic domain is indeed important not only for the physical interaction but also for functional antagonism by Vpu. Overall, we conclude that a physical interaction of Vpu with rhBST-2 via their cytoplasmic domains is necessary but not sufficient for functional antagonism, which depends on determinants within the Vpu TM domain.

The cytoplasmic domain of HIV-1 Vpu contributes to the physical interaction with, and functional antagonism of, chimpanzee BST-2. The pandemic form of HIV-1 group M has been traced back to SIVcpz, a virus causing infection in chimpanzees (66). SIVcpz carries a vpu gene, but its gene product is unable to antagonize chimpanzee BST-2 (chimpBST-2), even though HIV-1 Vpu has this capacity (43, 50). Interestingly, chimpsVpu carries the same 5-amino-acid motif in its cytoplasmic domain as rhBST-2 (chimpBST-2, Fig. 5C, right). ***, P < 0.001. Bars outlined in red represent combinations where the respective Vpu variant was able to antagonize the indicated BST-2 variant (as assessed in panel C). The expression of the KGC-tagged and KGN-tagged variants was assessed by immunoblotting as described for Fig. 1B. The KGN fragment encoded by the “tag-only” vector has a faster mobility and is not visible here. Faint bands in lanes 1 and 5 are nonspecific background. (C) The ability of SIVcpz VpucytNL to antagonize chimpanzee BST-2 via a cytoplasmic domain interaction was assessed by pulse-chase analysis as described in Materials and Methods. Open circles, empty vector; filled circles, NL4-3 Vpu; open squares, SIVcpz Vpu; filled squares, SIVcpz VpucytNL. Data are means ± standard errors of the means from two independent experiments. The statistical significance of the difference in virus release for SIVcpz Vpu and SIVcpz VpucytNL was determined by two-way ANOVA. ***, P < 0.01.
2 and 3). Surprisingly, however, the coexpression of chimvBST-2 with SIVcpz Vpu_{cytNL}, yielded BiFC signals even higher than those observed for the interaction with SIVcpz Vpu or HIV-1_{NL4-3} Vpu (Fig. 6B, compare bar 4 to bars 3 and 2). These results suggest that the cytoplasmic domain of HIV-1_{NL4-3} Vpu contributes significantly to the physical interaction with chimvBST-2. In agreement with this conclusion, SIVcpz Vpu_{cytNL} showed no detectable interaction with chimvBST-2_{cytThur} lacking the 5-amino-acid DDIWK motif (Fig. 6B, compare bars 7 and 8). Thus, the inability of SIVcpz Vpu to antagonize chimvBST-2 appears to be due to its inability to interact with the DDIWK motif in the cytoplasmic domain of chimvBST-2.

To further test this hypothesis, we performed a virus release experiment. Sequences encoding the cytoplasmic domain of Vpu overlap the 3' end of the env gene. Because of that, expression of SIV_{cpz} Vpu from a full-length molecular clone could affect Env expression. Therefore, we did not use the TZM-bl-based assay used in the preceding experiments, since potential effects on Env expression could affect the readout from this assay. Instead, we carried out pulse-chase experiments as described in Materials and Methods, using SIVcpz Vpu and, as a chimvBST-2 binding-competent control, SIVcpz Vpu_{cylNL}. We used C-terminally KGN-tagged Vpu constructs as shown in Fig. 6B in conjunction with NL4-3/Udel instead of using full-length provirus constructs expressing mutant Vpu. HIV-1_{NL4-3} Vpu was included as a control. Virus release from transfected 293T cells was measured over a 4-h time span (Fig. 6C). In agreement with previous reports (43, 50), we found that HIV-1 Vpu, but not SIVcpz Vpu, enhanced virus release in the presence of chimvBST-2. However, transfer of the HIV-1 Vpu cytoplasmic domain to SIVcpz Vpu (SIVcpz Vpu_{cylNL}) rescued the defect and rendered the resulting chimera capable of antagonizing chimvBST-2 with an efficiency similar to that of wild-type HIV-1 Vpu (Fig. 6C, compare filled squares with filled circles). Thus, the cytoplasmic domain of HIV-1_{NL4-3} Vpu is critical not only for the physical interaction with chimvBST-2 but also for the ability to functionally antagonize chimvBST-2.

**DISCUSSION**

The ongoing HIV epidemic, which has affected millions of people worldwide, originated from the zoonotic transmission of SIVcpz, a simian immunodeficiency virus normally infecting chimpanzees (66). As a result, HIV-1 and SIVcpz are very similar in their genetic structures. In particular, they both carry a vpu gene and lack a vpx gene, while most other SIV lineages, including SIVmac, carry vpx. The two best-studied functions of HIV-1 Vpu are the degradation of CD4 and the enhancement of virus particle secretion from infected cells (for a review, see reference 68). Interestingly, SIVcpz Vpu, while capable of inducing CD4 degradation, is unable to antagonize chimpanzee or human BST-2 for efficient virus release (43). Instead, SIVcpz—like most other SIVs—relies on Nef to overcome the BST-2-imposed restriction (43, 44, 49). Nef targets a 5-amino-acid motif in the cytoplasmic domain of simian SIV-2 (43, 44, 49). Of note, this motif is not found in human BST-2 and appears to have been lost more than 800,000 years ago (69). The transmission of SIV to humans is a fairly recent event, and it is not surprising that during adaptation to humans, the virus somehow shifted the burden of antagonizing BST-2 from Nef to Vpu (reviewed in reference 70). This switch seems to have been successful only in group M HIV-1 isolates, since the less common HIV-1 groups N, O, and P, which arose from independent zoonotic transmissions, seemed to have failed to evolve an effective BST-2 antagonist (43, 71).

Unlike Nef, which targets BST-2 via its cytoplasmic domain, HIV-1 Vpu has evolved to engage human BST-2 primarily via its TM domain in a species-specific manner (41–46). Because of this species specificity, Vpu was not predicted to support HIV-1 replication in macaques. Indeed, HIV-1 is unable to replicate in macaques, not only because of a BST-2 restriction but also because of restrictions imposed by APOBEC3G and Trim5α (72, 73). Nevertheless, the macaque system has gained importance for HIV research and is currently the most widely used nonhuman primate model for vaccine development and the study of host immune responses. To bypass the restrictions encountered by HIV-1, investigators are using chimeric SIV variants that carry HIV-1 env sequences in conjunction with SIV gag, pol, vif, and nef. Because of the overlap of the vpu open reading frame with the env gene, simian-human immunodeficiency virus (SHIV) chimeras typically also carry the HIV-1 vpu gene. Surprisingly, experiments performed with SHIV-infected pig-tailed macaques suggested a correlation between Vpu expression and viral pathogenesis (74, 75). Of note, the increased pathogenic potential of SHIV in infected pig-tailed macaques mapped to the Vpu TM domain, pointing to BST-2 as the target of Vpu (76). Indeed, our own results gained from SHIV-infected rhesus macaques demonstrate that at least some HIV-1 Vpu proteins have an expanded host range and are capable of targeting rhesus macaque as well as human BST-2 (47).

Previous studies had used coimmunoprecipitation assays (26, 28, 29, 63, 65), FRET (64), and NMR spectroscopy (31) to demonstrate the physical interaction of Vpu with human BST-2 via their TM domains. Our approach was to assess the mechanistic basis of the expanded Vpu host range by studying Vpu-BST-2 interactions using a bimolecular fluorescence complementation (BiFC) assay as reported previously (25). Our results showing the physical interaction between HIV-1 Vpu and huBST-2 by a BiFC assay in this study faithfully reproduce previous results from co-IP studies (26–28, 63), from a FRET study (64), and from a study using NMR (31). In addition, our assay also reproduced the less-efficient interactions of Vpu_{cylNL} and Vpu_{14/22} (A14LW 22A) with huBST-2 previously shown by co-IP (28, 65), by FRET (64), or by BiFC assay (25). Indeed, using this assay, we were able to document robust interactions of HIV-1 Vpu with huBST-2 via their TM domains, previously shown by other groups (26, 28, 29, 63, 65). However, our results also make clear that the binding of Vpu to BST-2 is not sufficient for BST-2 antagonism, since DH12 Vpu, but not NL4-3 Vpu, was able to antagonize rhBST-2 even though these two Vpu proteins interacted equally well with rhBST-2 in our BiFC assay (Fig. 1B). The postbinding steps required for BST-2 antagonism remain unclear. However, we found that the introduction of an I46T mutation into the rhBST-2 TM domain, which rendered the protein sensitive to antagonism by NL4-3 Vpu (48), did not affect the protein-protein interaction in our current analysis (Fig. 1B). Along the same lines, mutating a single residue in the TM domain of NL4-3 Vpu (A14L) resulted in a loss of activity against huBST-2 (65) without affecting the protein-protein interaction in our BiFC assay (data not shown). Thus, we can conclude that the binding of Vpu to BST-2 is necessary but not sufficient for functional antagonism.

As expected from our functional studies, Vpu also interacted with rhBST-2 in our BiFC assay (Fig. 1B, 2B, and 5B). Surprisingly, however, and in contrast to the interaction with huBST-2,
the interaction of Vpu with rhBST-2 involved sequences in the cytoplasmic domain of BST-2. Even more surprisingly, the cytoplasmic sequences in rhBST-2 involved in the interaction with Vpu mapped to the same 5-amino-acid motif [(G/D)DIWK] that is missing from huBST-2 and that forms the target of SIV Nef. The interaction of Vpu with the cytoplasmic domain was functionally relevant and was sufficient to confer at least partial antagonistic activity on a Vpu variant (Vpu14/22) (Fig. 4E and F) previously shown to be nonfunctional due to a lack of interaction with human BST-2 (65). The results from our current study lead us to amend the previous assessment that Vpu targets BST-2 through TM domain interactions by concluding that, at least for macaque and chimpanzee BST-2, the cytoplasmic domain of BST-2 contributes to the physical interaction with Vpu. The fact that HIV-1 Vpu has the ability to interact with a sequence motif not found in human BST-2 raises interesting evolutionary questions, since the sequence is present in the BST-2 of the chimpanzee, which is the natural host for the Vpu-encoding SIVcpz. Yet Vpu from SIVcpz does not antagonize chimpanzee BST-2 (43). Instead, the five-residue motif is necessary for antagonism by SIVcpz Nef (50, 51). Our results suggest that SIVcpzNef does not antagonize chimpanzee BST-2 due to a lack of physical interaction with chimpBST-2 (Fig. 6). This is suggested by the fact that replacing the cytoplasmic domain of SIVcpz Vpu with that of HIV-1-HD4 Vpu renders the protein capable of both physically interacting with and functionally antagonizing chimpBST-2. Taking our results together, our study revealed the importance of the Vpu cytoplasmic domain for the interaction with the (G/D)DIWK motif in monkey and great ape BST-2.

Investigations to determine what sequences in Vpu are involved in the interaction with the BST-2 cytoplasmic domain are ongoing. However, based on the positioning of the (G/D)DIWK motif relative to the BST-2 transmembrane domain, we would predict that the sequences in Vpu required for the interaction with the (G/D)DIWK motif map to one or both of its cytoplasmic helices, a situation similar to that described for the interaction of Vpu with the cytoplasmic domain of CD4 (77, 78).

ACKNOWLEDGMENTS

We thank Eri Miyagi, Amy Andrew, Chia-Yen Chen, Sandra Kao, Sarah Welbourn, Robert C. Walker, Jr., Tomoko Kobayashi, Masashi Shingali, and Haruka Yoshii-Kamiyama for helpful suggestions and critical comments on the manuscript. We thank Alicia Buckler-White and Ronald Plisika for conducting nucleotide sequence analyses. We further thank F. Kirchhoff and J. Martin-Serrano for reagents.

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (K.S.) and by grants from the Grants-in-Aid for Scientific Research (24115008 and 24390112) and Research on HIV/AIDS from the Ministry of Health, Labor and Welfare of Japan (to Y.K.).

REFERENCES

Full text not available...


